Bausch Health Companies Inc. Research and Development in Process
Bausch Health Companies Inc. (BHC) reported Research and Development in Process of $1.00 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-23.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-02-23
- Bausch Health Companies Inc. research and development in process for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- Bausch Health Companies Inc. research and development in process for the quarter ending 2022-09-30 was $0.00.
- Bausch Health Companies Inc. research and development in process for the quarter ending 2022-06-30 was $1.00M, a 0.00% change year-over-year.
- Bausch Health Companies Inc. research and development in process for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- Bausch Health Companies Inc. research and development in process for fiscal 2022 was $1.00M, a 87.50% decline from fiscal 2021.
- Bausch Health Companies Inc. research and development in process for fiscal 2021 was $8.00M, a 75.00% decline from fiscal 2020.
- Bausch Health Companies Inc. research and development in process for fiscal 2020 was $32.00M.
- Bausch Health Companies Inc. research and development in process for fiscal 2017 was $5.00M, a 85.29% decline from fiscal 2016.
| Period end | Research and Development in Process 3 month | Research and Development in Process 3 month as first filed | Research and Development in Process 6 month | Research and Development in Process 6 month as first filed | Research and Development in Process 9 month | Research and Development in Process 9 month as first filed | Research and Development in Process 12 month | Research and Development in Process 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $0.00 derived: sum of 2 quarters · filed 2023-02-23 | $1.00M derived: sum of 3 quarters · filed 2023-02-23 | $1.00M 10-K · filed 2023-02-23 | ||||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-03 | $1.00M derived: sum of 2 quarters · filed 2022-11-03 | $1.00M 10-Q · filed 2022-11-03 | $6.00M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2022-06-30 | $1.00M 10-Q · filed 2022-08-09 | $1.00M 10-Q · filed 2022-08-09 | $6.00M derived: sum of 3 quarters · filed 2023-02-23 | $6.00M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-10 | $5.00M derived: sum of 2 quarters · filed 2023-02-23 | $5.00M derived: sum of 3 quarters · filed 2023-02-23 | $6.00M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2021-12-31 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $5.00M derived: sum of 2 quarters · filed 2023-02-23 | $6.00M derived: sum of 3 quarters · filed 2023-02-23 | $8.00M 10-K · filed 2023-02-23 | ||||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-03 | $1.00M derived: sum of 2 quarters · filed 2022-11-03 | $3.00M 10-Q · filed 2022-11-03 | $15.00M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2021-06-30 | $1.00M 10-Q · filed 2022-08-09 | $3.00M 10-Q · filed 2022-08-09 | $15.00M derived: sum of 3 quarters · filed 2023-02-23 | $27.00M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2021-03-31 | $2.00M 10-Q · filed 2022-05-10 | $14.00M derived: sum of 2 quarters · filed 2023-02-23 | $26.00M derived: sum of 3 quarters · filed 2023-02-23 | $33.00M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2020-12-31 | $12.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $24.00M derived: sum of 2 quarters · filed 2023-02-23 | $31.00M derived: sum of 3 quarters · filed 2023-02-23 | $32.00M 10-K · filed 2023-02-23 | ||||
| 2020-09-30 | $12.00M 10-Q · filed 2021-11-02 | $19.00M derived: sum of 2 quarters · filed 2021-11-02 | $20.00M 10-Q · filed 2021-11-02 | $52.00M derived: sum of 4 quarters · filed 2022-05-11 | ||||
| 2020-06-30 | $7.00M 10-Q · filed 2021-08-03 | $8.00M 10-Q · filed 2021-08-03 | $40.00M derived: sum of 3 quarters · filed 2022-05-11 | $41.00M derived: sum of 4 quarters · filed 2022-05-11 | ||||
| 2020-03-31 | $1.00M 10-Q · filed 2021-05-04 | $33.00M derived: sum of 2 quarters · filed 2022-05-11 | $34.00M derived: sum of 3 quarters · filed 2022-05-11 | $41.00M derived: sum of 4 quarters · filed 2022-05-11 | ||||
| 2019-12-31 | $32.00M derived: 8-K 12 month − 10-Q 9 month · filed 2022-05-11 | $33.00M derived: sum of 2 quarters · filed 2022-05-11 | $40.00M derived: sum of 3 quarters · filed 2022-05-11 | $41.00M 8-K · filed 2022-05-11 | ||||
| 2019-09-30 | $1.00M 10-Q · filed 2020-11-03 | $8.00M derived: sum of 2 quarters · filed 2020-11-03 | $9.00M 10-Q · filed 2020-11-03 | |||||
| 2019-06-30 | $7.00M 10-Q · filed 2020-08-06 | $8.00M 10-Q · filed 2020-08-06 | ||||||
| 2019-03-31 | $1.00M 10-Q · filed 2020-05-07 | |||||||
| 2018-12-31 | $1.00M 8-K · filed 2021-05-04 | |||||||
| 2018-03-31 | $1.00M 10-Q · filed 2019-05-06 | |||||||
| 2017-12-31 | $5.00M 10-K · filed 2020-02-19 | |||||||
| 2016-12-31 | $14.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-20 | $19.50M derived: sum of 2 quarters · filed 2019-02-20 | $34.00M 10-K · filed 2019-02-20 | |||||
| 2016-09-30 | $5.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $20.00M 10-Q · filed 2016-11-09 | ||||||
| 2016-06-30 | $14.50M 10-Q · filed 2016-08-09 | |||||||
| 2015-12-31 | -$2.10M derived: 8-K 12 month − 10-Q 9 month · filed 2018-08-10 | $93.70M derived: sum of 2 quarters · filed 2018-08-10 | $106.00M derived: sum of 3 quarters · filed 2018-08-10 | $106.00M 8-K · filed 2018-08-10 | $144.50M 10-K · filed 2016-04-29 | |||
| 2015-09-30 | $95.80M 10-Q · filed 2015-10-26 | $108.10M derived: sum of 2 quarters · filed 2015-10-26 | $108.10M 10-Q · filed 2016-11-09 | |||||
| 2015-06-30 | $12.30M 10-Q · filed 2015-07-28 | $12.30M 10-Q · filed 2016-08-09 | ||||||
| 2014-12-31 | -$300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $19.60M derived: sum of 2 quarters · filed 2017-03-01 | $20.00M derived: sum of 3 quarters · filed 2017-03-01 | $20.00M 10-K · filed 2017-03-01 | $21.00M 10-K · filed 2015-02-25 | |||
| 2014-09-30 | $19.90M 10-Q · filed 2015-10-26 | $20.30M derived: sum of 2 quarters · filed 2015-10-26 | $20.30M 10-Q · filed 2015-10-26 | $55.40M derived: sum of 4 quarters · filed 2016-04-29 | ||||
| 2014-06-30 | $400.00K 10-Q · filed 2015-07-28 | $400.00K 10-Q · filed 2015-07-28 | $35.50M derived: sum of 3 quarters · filed 2016-04-29 | $159.50M derived: sum of 4 quarters · filed 2016-04-29 | ||||
| 2014-03-31 | $12.00M 10-Q · filed 2014-05-09 | $35.10M derived: sum of 2 quarters · filed 2016-04-29 | $159.10M derived: sum of 3 quarters · filed 2016-04-29 | $163.90M derived: sum of 4 quarters · filed 2016-04-29 | ||||
| 2013-12-31 | $23.10M derived: 10-K 12 month − 10-Q 9 month · filed 2016-04-29 | $147.10M derived: sum of 2 quarters · filed 2016-04-29 | $151.90M derived: sum of 3 quarters · filed 2016-04-29 | $151.90M 10-K · filed 2016-04-29 | $153.64M 10-K · filed 2014-02-28 | |||
| 2013-09-30 | $124.00M 10-Q · filed 2014-10-24 | $123.98M 10-Q · filed 2013-11-01 | $128.80M derived: sum of 2 quarters · filed 2014-10-24 | $128.80M 10-Q · filed 2014-10-24 | $128.81M 10-Q · filed 2013-11-01 | $146.63M derived: sum of 4 quarters · filed 2015-02-25 | ||
| 2013-06-30 | $4.80M 10-Q · filed 2014-08-01 | $4.83M 10-Q · filed 2013-08-07 | $4.80M 10-Q · filed 2014-08-01 | $4.83M 10-Q · filed 2013-08-07 | $22.63M derived: sum of 3 quarters · filed 2015-02-25 | $167.93M derived: sum of 4 quarters · filed 2015-02-25 | ||
| 2013-03-31 | $0.00 10-Q · filed 2014-05-09 | $17.83M derived: sum of 2 quarters · filed 2015-02-25 | $163.13M derived: sum of 3 quarters · filed 2015-02-25 | $167.70M derived: sum of 4 quarters · filed 2015-02-25 | ||||
| 2012-12-31 | $17.83M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-25 | $163.13M derived: sum of 2 quarters · filed 2015-02-25 | $167.70M derived: sum of 3 quarters · filed 2015-02-25 | $167.70M 10-K · filed 2015-02-25 | $189.90M 10-K · filed 2013-02-28 | |||
| 2012-09-30 | $145.30M 10-Q · filed 2013-11-01 | $149.87M derived: sum of 2 quarters · filed 2013-11-01 | $149.87M 10-Q · filed 2013-11-01 | |||||
| 2012-06-30 | $4.57M 10-Q · filed 2013-08-07 | $4.57M 10-Q · filed 2013-08-07 | ||||||
| 2011-12-31 | $105.20M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | $105.20M derived: sum of 2 quarters · filed 2014-02-28 | $107.20M derived: sum of 3 quarters · filed 2014-02-28 | $109.20M 10-K · filed 2014-02-28 | ||||
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-05 | $2.00M derived: sum of 2 quarters · filed 2012-11-05 | $4.00M 10-Q · filed 2012-11-05 | |||||
| 2011-06-30 | $2.00M 10-Q · filed 2012-08-03 | $4.00M 10-Q · filed 2012-08-03 | ||||||
| 2011-03-31 | $2.00M 10-Q · filed 2012-05-04 | |||||||
| 2010-12-31 | $89.25M 10-K · filed 2013-02-28 | |||||||
| 2009-12-31 | $59.35M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |